Cargando…

Genetics of Neurogenic Orthostatic Hypotension in Parkinson’s Disease, Results from a Cross-Sectional In Silico Study

The genetic basis of Neurogenic Orthostatic Hypotension (NOH) in Parkinson’s disease (PD) has been inadequately explored. In a cross-sectional study, we examined the association between NOH and PD-related single-nucleotide polymorphisms (SNPs) and mapped their effects on gene expression and metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chevalier, Guenson, Udovin, Lucas, Otero-Losada, Matilde, Bordet, Sofia, Capani, Francisco, Luo, Sheng, Goetz, Christopher G., Perez-Lloret, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046202/ https://www.ncbi.nlm.nih.gov/pubmed/36979316 http://dx.doi.org/10.3390/brainsci13030506

Ejemplares similares

The Genetic Basis of Probable REM Sleep Behavior Disorder in Parkinson’s Disease
por: Perez-Lloret, Santiago, et al.
Publicado: (2023)

Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic
por: Otero-Losada, Matilde, et al.
Publicado: (2020)

The Renin–Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene
por: Kobiec, Tamara, et al.
Publicado: (2021)

Role of Astrocytic Dysfunction in the Pathogenesis of Parkinson's Disease Animal Models from a Molecular Signaling Perspective
por: Udovin, Lucas, et al.
Publicado: (2020)

Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
por: Cutsforth-Gregory, Jeremy K., et al.
Publicado: (2019)

Neurogenic orthostatic hypotension: the very basics
por: Kaufmann, Horacio, et al.
Publicado: (2017)

Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease
por: McCullough, Peter A.
Publicado: (2019)

Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Goodman, Brent P., et al.
Publicado: (2017)

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Claassen, Daniel, et al.
Publicado: (2017)

Editorial: Neuroprotection and Disease Modification in Parkinson’s Disease
por: Otero-Losada, Matilde, et al.
Publicado: (2021)

Editorial: Neuroprotection and disease modification in Parkinson’s disease: Volume II
por: Otero-Losada, Matilde, et al.
Publicado: (2023)

Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management
por: Metzler, Manuela, et al.
Publicado: (2012)

Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa
por: Isaacson, Stuart H, et al.
Publicado: (2014)

Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Lew, Mark, et al.
Publicado: (2017)

Neurogenic orthostatic hypotension – management update and role of droxidopa
por: Vijayan, Joy, et al.
Publicado: (2015)

Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
por: François, Clément, et al.
Publicado: (2019)

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
por: Biaggioni, Italo, et al.
Publicado: (2017)

Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies
por: Kalra, Dinesh K, et al.
Publicado: (2020)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
Publicado: (2020)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
por: Byun, Jung‐Ick, et al.
Publicado: (2019)

Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
por: Eisenhofer, Graeme, et al.
Publicado: (2021)

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
por: Hauser, Robert A., et al.
Publicado: (2016)

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
por: Kremens, Daniel, et al.
Publicado: (2017)

Neurogenic orthostatic hypotension with Parkinson's disease as a cause of syncope: A case report
por: Li, Ya, et al.
Publicado: (2021)

Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
por: Eschlböck, Sabine, et al.
Publicado: (2017)

Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension
por: Raj, Satish R, et al.
Publicado: (2019)

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension
por: Mehdirad, Ali, et al.
Publicado: (2017)

Erratum to: Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
por: Kaufmann, Horacio
Publicado: (2017)

Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension
por: Isaacson, Stuart H., et al.
Publicado: (2021)

The effects of caffeine in adults with neurogenic orthostatic hypotension: a systematic review
por: Gibbon, Jake Ryan, et al.
Publicado: (2021)

Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
por: Amjad, Fahd, et al.
Publicado: (2021)

Neurogenic Orthostatic Hypotension: a Common Complication of Successful Pancreas Transplantation
por: Kuten, Samantha A., et al.
Publicado: (2021)

Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review
por: Hoxhaj, Pranvera, et al.
Publicado: (2023)

The Management of Orthostatic Hypotension in Parkinson’s Disease
por: Sánchez-Ferro, Álvaro, et al.
Publicado: (2013)

Management of Orthostatic Hypotension in Parkinson’s Disease
por: Fanciulli, Alessandra, et al.
Publicado: (2020)

Delayed orthostatic hypotension in Parkinson’s disease
por: Yoo, Sang-Won, et al.
Publicado: (2021)

Neuroprotection from protein misfolding in cerebral hypoperfusion concurrent with metabolic syndrome. A translational perspective
por: Bordet, Sofía, et al.
Publicado: (2023)

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus
por: Vernino, Steven, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lpe2s8n8t5kp7r3aj26ff9v3va